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We describe polyclonal spread of colistin-resistant 
Klebsiella pneumoniae in an acute general hospital in 
Italy. Between June and December 2011, 58 colistin-
resistant K. pneumoniae isolates were recovered from 
28 patients admitted to different wards, but mainly 
in the intensive care units. All isolates were tested 
for drug susceptibility and the presence of beta-lac-
tamase (bla) genes. Clonality was investigated by 
repetitive extragenic palindromic (rep)-PCR and multi-
locus sequence typing (MLST). Fifty-two isolates had 
minimum inhibitory concentrations (MICs) for colistin 
of 6–128 mg/L, carried blaKPC3 and were attributed to 
sequence type ST258. The remaining six isolates were 
susceptible to carbapenems, exhibited MICs for colis-
tin of 3–32 mg/L, and belonged to two different types, 
ST15 and ST273. Rep-PCR included all isolates in three 
clusters, one containing all ST258 KPC-3-producing 
isolates and two containing ST15 and ST273 isolates. 
Cross-transmission containment measures and inten-
sification of staff and environmental hygiene could not 
stop the outbreak. Selective pressure and horizontal 
transmission probably contributed to emergence and 
spread of three different strains of colistin-resistant 
K. pneumoniae in the hospital. Strict implementation 
of the above measures and a wider awareness of the 
antimicrobial resistance threat are crucial to preserve 
the last therapeutic options of the multidrug-resistant 
Gram-negative infections.
Introduction
Infections caused by Gram-negative pathogens resist-
ant to carbapenems are emerging as a consequence 
of the intensive use of these compounds [1]. Klebsiella 
pneumoniae carbapenemase (KPC)-producing organ-
isms in particular are of great concern from a pub-
lic health and clinical point of view, because these 
infections have a high crude mortality rate and the 
therapeutic options are limited [2,3]. Most of them are 
susceptible only to gentamicin, polymyxins and tigecy-
cline [2,3]. 
 
Polimyxins are considered as the last resort for 
treatment of infections with carbapenem-resistant 
Gram-negative bacteria. However, resistance to these 
compounds has begun to emerge, although infre-
quently [4-8]. Selective pressure by the increased use 
of colistin and clonal expansion through horizontal 
transmission have generated clusters of cases infected 
with multiresistant K. pneumoniae strains that have 
been generally attributed to the international epidemic 
clone ST258 [4,7].
In Italy, KPC-producing K. pneumoniae strains are 
endemic [9]. After the first report in 2008 [10], KPC-
producing K. pneumoniae have widely spread, and 
several hospital outbreaks have been described [7,11-
14]. Recently the European Antimicrobial Resistance 
Surveillance Network (EARS-Net)’s surveillance system 
for Italy has shown that the prevalence of carbapenem 
resistance in K. pneumoniae has risen from 1–2% in 
the years 2006–09 to 15% in 2010 [15]. An outbreak 
caused by colistin-resistant isolates of KPC-producing 
K. pneumoniae belonging to sequence type ST258 has 
also been described [7].
In 2008, the II intensive care unit (ICU) of the ARNAS 
general hospital Civico, di Cristina e Benfratelli in 
Palermo, Italy, was affected by the first outbreak of 
KPC3-K. pneumoniae ST258 occurring in Sicily [14]. 
Since then, after a brief transient period during which 
the outbreak strain was not detected, colonisations 
or infections with KPC3-K. pneumoniae have become 
endemic in the hospital. 
Here we describe the polyclonal spread of colistin-
resistant K. pneumoniae on different wards of the same 
hospital in the period from June to December 2011. 
Materials and methods 
Setting
The ARNAS general hospital Civico, Di Cristina e 
Benfratelli in Palermo is the largest acute general hos-
pital in Sicily. It had during the study period (June to 
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December 2011) a capacity of 901 beds in total, includ-
ing 24 beds in two general intensive care units (ICUs), 
identified as I and II ICU. Each unit has dedicated nurs-
ing and medical staff. At the time of the outbreak, the 
infection control policy in the ICUs did not include 
routine surveillance cultures or screening of high risk 
patients on admission. Special attention was given to 
hand hygiene measures, with an alcoholic hand rub 
solution placed in the proximity of every ICU bed or 
provided as a personal pocket dispenser. Furthermore, 
the hospital did not have a policy of restricting the 
use of antibiotic drugs or clinical practice guidelines 
for infections with multidrug-resistant pathogens. The 
hospital microbiology laboratory regularly provided 
susceptibility results to first and second line antibi-
otics, but a structured system for the surveillance of 
antimicrobial resistance had not been implemented. 
However, a hospital formulary and an antibiotic policy 
committee were present. Antibiotic consumption was 
monitored through data from the hospital’s pharmacy, 
but the defined daily dosage (DDD) was not measured. 
Microbiology and molecular epidemiology
All colistin-resistant K. pneumoniae isolates, irrespec-
tive of their source patient and clinical sample, were 
subjected to further phenotypic and molecular analy-
sis. Data about time and ward of isolation, clinical 
sample and antibacterial drug susceptibility pattern 
were evaluated using the records of the microbiology 
laboratory. 
Bacterial identification and antibiotic susceptibility 
testing were initially performed at the Laboratory of 
Microbiology of the ARNAS general hospital Civico, 
di Cristina e Benfratelli using the VITEK-2 automated 
system (bio-Mérieux, Marcy l’Etoile, France). Minimum 
inhibitory concentrations (MICs) of imipenem (IMP), 
meropenem (MEM) and colistin (CT) were also deter-
mined by using Etest (AB Biodisk, Solna, Sweden), 
following the guidelines of the European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) [16]. 
Escherichia coli ATCC 25922 was used as quality con-
trol strain. Susceptibility and resistance categories 
were assigned according to the EUCAST breakpoints 
[16]. Phenotypic screening for the presence of carbap-
enemases or overexpression of AmpC in combination 
with porin loss was performed by a commercial syn-
ergy test (Rosco Diagnostica, Taastrup, Denmark).
The isolates were subjected to polymerase chain 
reaction (PCR) to screen for the presence of blaKPC, 
blaSHV, blaTEM, blaCTX-M, blaVIM and blaIMP, as described 
previously [17]. DNA sequencing was performed on both 
strands of the PCR amplification products. Results were 
compared and aligned with reference sequences using 
the online BLAST database and CLUSTAL W software.
Clonality of the K. pneumoniae isolates was investi-
gated by molecular typing, using the repetitive extra-
genic palindromic (rep)-PCR methodology. Rep-PCR was 
performed using the DiversiLab system (bioMérieux, 
Figure 1
Infections/colonisations with colistin-resistant Klebsiella pneumoniae strains, ARNAS general hospital Civico,  
di Cristina e Benfratelli, Palermo, June–December 2011(n=28)
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Marcy l’Étoile, France). The model 2100 bioanalyzer 
and LabChip reagents (Agilent Technologies Inc., Palo 
Alto, CA) were used for DNA separation and sizing. DNA 
fragment patterns were then analysed by using the 
modified Kullback-Leibler coefficient pairwise pattern 
matching and the unweighted pair group method with 
arithmetic mean (UPGMA) clustering algorithm [18]. In 
addition, multilocus sequence typing (MLST) was per-
formed and sequence types were determined using the 
K. pneumoniae MLST database [19].
Results
Between June and December 2011, 58 colistin-resist-
ant K. pneumoniae isolates were recovered from 28 
patients. The index case was a patient staying in the 
I ICU, from whom a colistin-resistant K. pneumoniae 
isolate was identified on 8 June 2011. The epidemic 
curve of infections/colonisations with colistin-resistant 
K. pneumoniae strains in the hospital is shown in 
Figure 1.
The main characteristics of the isolates are summa-
rised in the Table. Because the index case proved to be 
infected by two different clones of colistin-resistant K. 
pneumoniae, all isolates from subsequent cases were 
submitted to phenotypic and genetic analysis. 
All isolates, except for six (isolates number 3, 5, 7, 9, 21 
and 25 from five different patients) were resistant to all 
beta-lactams and beta-lactam/beta-lactamase inhibi-
tor combinations (ampicillin, ampicillin/sulbactam, 
amoxicillin/clavulanic acid, third generation cephalo-
sporins, piperacillin, piperacillin/tazobactam, ticarcil-
lin, ticarcillin/clavulanic acid, aztreonam, imipenem, 
meropenem), fluoroquinolones (ciprofloxacin, levoflox-
acin), co-trimoxazole and aminoglycosides (amikacin, 
netilmicin, tobramycin). Only 10 of the 52 isolates were 
found to be susceptible to gentamicin. All 52 isolates 
were resistant to colistin (Table), with MICs ranging 
from 3 mg/L to 128 mg/L. 
Phenotypic screening for the presence of carbapen-
emases or AmpC/porin loss suggested KPC produc-
tion. PCR analysis and nucleotide sequencing revealed 
that the 52 isolates carried the blaKPC-3 gene as well as 
an SHV-11 extended-spectrum beta-lactamase (ESBL) 
enzyme. MLST attributed these isolates with the 
sequence type ST258 (Table).
The remaining six isolates were resistant to beta-lac-
tams and beta-lactam/beta-lactamase inhibitor combi-
nations, but susceptible to carbapenems (Table). They 
were also susceptible to cotrimoxazole, and resistant 
to fluoroquinolones and aminoglycosides, except ami-
kacin. MICs of colistin ranged from 3 mg/L to 32 mg/L. 
MLST attributed the six isolates to two different STs, 
ST15 and ST273. PCR analysis and nucleotide sequenc-
ing of the amplicons identified blaSHV-12 in the four ST273 
K. pneumoniae isolates, whereas blaSHV-28 and blaCTX-M-15 
were detected in the two ST15 isolates (Table).
Rep-PCR confirmed that the colistin-resistant isolates 
belonged to three different clusters, one that contained 
all ST258 KPC-3 producing isolates, and two clusters 
with unrelated patterns including the ST15 and ST273 
isolates (Figure 2).
Control measures
During the period from June to December 2011, colis-
tin-resistant ST258 KPC-3-producing K. pneumoniae 
spread on six different wards of the acute general 
hospital Civico, di Cristina e Benfratelli, although its 
epicenter was in the I ICU, where 16 of 28 patients 
were staying at the time of the isolation of the colistin-
resistant strain (Table). 
Infection control measures were strengthened on all 
affected wards following the detection and confirma-
tion of the first colistin-resistant K. pneumoniae iso-
late. In particular, hand hygiene, contact precautions 
were improved, including dedicated use of patient¬ 
care equipment and use of disposable gloves and 
aprons, and environmental cleaning. The ICUs were 
thoroughly cleaned and respiratory equipment disin-
fected. Because of insufficient bed capacity, isolation 
was not feasible in either ICU, but colonised or infected 
patients were cohorted in the II ICU, and spatially 
segregated in the I ICU as well as the other wards. 
Compliance with hand hygiene and environmental 
cleaning procedures were monitored. Adherence of the 
personnel was strongly promoted by weekly meetings 
between healthcare workers and the hospital infection 
control team. 
Despite these measures, the outbreak developed 
further, and additional isolates were detected. 
The outbreak peaked in July and August 2011, but 
new cases occurred in the following months. In 
December 2011, three new cases were still recognised 
(Table and Figure 1). 
Discussion
Emergence of colistin-resistant strains among the 
expanding population of multi-resistant Gram-negative 
bacteria is an inevitable consequence of the increas-
ing use of this antimicrobial agent [20]. Mono- or mul-
ticlonal outbreaks of colistin-resistant, KPC-producing 
K. pneumoniae have been described in hospitals in 
many countries, for example Greece, South Korea and 
the United States [4-6,8]. In Italy, an outbreak involv-
ing eight patients was reported in 2010. It occurred in 
two different hospitals in Catania, the same region in 
Sicily also affected by the ongoing outbreak described 
here [7]. Most often, outbreaks due to KPC-producing K. 
pneumoniae have been attributed to the ST258 clone. 
Also in our case, a KPC-3 producing, ST258 strain was 
responsible for the largest proportion of infections/col-
onisations, and cross-transmission between patients 
was likely to be the key factor of its clonal expan-
sion. We hypothesise that the main obstacles prevent-
ing interruption of the transmission chain were the 
extended length of stay of some critically ill patients in 
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the ICU as long-term reservoirs of multidrug-resistant 
organisms, as well as the need to move some patients 
between different wards of the hospital.
A further reason for concern was the detection of other 
K. pneumoniae isolates, belonging to ST15 and ST273, 
that were resistant to colistin, albeit at lower MICs than 
the ST258 clone, and susceptible to carbapenems. ST15 
isolates with an indistinguishable genetic antibiotic 
resistance pattern have recently been reported as epi-
demic in Denmark [21]. Moreover, metallo-beta-lacta-
mase producing K. pneumoniae strains of ST273, along 
with ST147, have recently been exported from southern 
Europe to Scandinavia [22]. ST273 is a single-locus var-
iant of ST147 that has previously been associated with 
CTX-M-15-producing isolates from several countries, 
for example Hungary [23], Italy [24], Spain [25] and 
Tunisia [26]. An ST147 K. pneumoniae producing NDM-1 
and CTX-M-15 has been recently reported in a patient 
returning from India to Canada, suggestive of the likely 
prominent role of this clone in the intercontinental dis-
semination of antimicrobial resistance [27]. However, 
none of our patients carrying these strains (ST15 and 
ST273) had a history of recent travel to other European 
countries. Consequently, in our setting colistin resist-
ance is more likely to have emerged through selec-
tive pressure and spread through cross-transmission. 
It is also noteworthy that colistin resistance involved 
strains belonging to globally successful multi-resistant 
clonal complexes [28]. 
Treatment with colistin and its duration have been 
proven to be major risk factors for the emergence of 
resistance. They have also been associated with other 
multi-resistant Gram-negative organisms intrinsically 
resistant to colistin, such as Proteus, Providencia 
and Morganella [20]. A further reason for concern 
is the parallel development of colistin resistance in 
Acinetobacter baumannii, a possible co-infecting or co-
colonising organism found mainly in ICU patients and 
other critically ill patients [29]. 
With the increasing need to use colistin for the treat-
ment of multidrug-resistant Gram-negative pathogens, 
it is likely that healthcare-associated emergence and 
spread of colistin resistance will rise. Implementation 
of strict infection control measures, antibiotic steward-
ship and widespread promotion of better awareness 
of the danger of antimicrobial resistance, are crucial 
to preserve the last therapeutic options for infections 
with multidrug-resistant Gram-negative bacteria.
Figure 2
Rep-PCR analysis of colistin-resistant Klebsiella 
pneumoniae isolates, ARNAS general hospital Civico, 
di Cristina e Benfratelli, Palermo, June–December 2011 
(n=28) 
The dendrogram includes 23 representative KPC-3-producing 
K. pneumoniae isolates from 23 different patients and five 
carbapenem-susceptible K. pneumoniae isolates from five 
different patients. Isolates with ≥95% similarity were considered 
related.
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